Nanolattix Chairperson Dr. Zhican Qu Attends BIO 2025, Showcasing China's Biopharma Innovation
Release time:
2025-07-09
*Boston, USA – June 16-19, 2025* – Dr. Zhican Qu, Chairperson of Nanolattix, alongside Elizabeth Wu, Head of International Business, participated in the 2025 BIO International Convention, the world's premier biotech partnering event held in Boston. The delegation actively engaged in global partnership building to accelerate the overseas expansion of Nanolattix's innovative therapeutics.
Spotlight on Nanolattix’s Breakthrough Innovations
On June 16, Dr. Qu delivered a keynote presentation highlighting Nanolattix’s pioneering advancements in biopharmaceuticals, underscoring China’s growing prowess in cutting-edge drug development. She introduced the company’s proprietary BioLattix™ technology platform, which has enabled the development of over 10 novel antibody-drug conjugates (ADCs) and radiopharmaceutical drug conjugates (RDCs) targeting critical disease areas.
Key pipeline highlights include:
T320-ADC, a potential best-in-class therapy for aggressive solid tumors (cervical, pancreatic, and ovarian cancers), now in clinical trials.
B836, a first-in-class bispecific ADC demonstrating superior preclinical efficacy compared to three commercially available ADC drugs.
Promising advancements in RDC therapeutics, marking significant progress in radiopharmaceutical innovation.
BIO 2025: A Global Stage for Biotech Collaboration
The BIO International Convention brings together leading pharmaceutical companies, biotech innovators, and investors worldwide to foster cross-border partnerships and accelerate commercialization. Nanolattix remains committed to open collaboration, seeking strategic alliances with global biopharma leaders to co-develop next-generation therapies.
"We are excited to share our innovations with the global biotech community and explore transformative partnerships," said Dr. Qu. "Nanolattix is poised to deliver breakthrough medicines that address unmet medical needs worldwide."
Tag:
Previous Page
Previous Page:
recommend News
Share
